History
The REPViT brand was created in 2020 to market and commercialise an innovative diagnostic platform for both virus and bacterial infections based on Indicate Solutions' proprietary IP (EP20382499.0).
The aim of REPViT is to offer fast, affordable and easy to use diagnostic solutions for consumers and professionals to detect SARS-CoV-2, Influenza and other viruses and bacteria at home and on the go, in less than 15 minutes using saliva.
The REPViT device concept is a rapid Nucleic Acid Test (NAT) equivalent to PCR in a single-use handheld over the counter test format, similar to a pregnancy test.
The company
The REPViT Solution
1) Scalability
The REPViT technology does not require any manufacturing that is not available at large scale (i.e. no electronics, microfluidics, optics etc), does not use enzymes and does not require large laboratory equipment or specialist staff. This allows for rapid mass production and deployment of the test to meet demand in order to contain even very virulent infections.
2) Flexibility
The REPViT technology is easy to use, not sensitive to temperature and can be prepared in a home-test kit format, applied in all geographies, and most circumstances such as work, school, transport, hospital, care home or football stadium. It can be adapted to detect additional virus based, or bacterial, infectious diseases.
3) Marketability
Due to the simplicity of handling and application of the REPViT test, it can be sold as a B2B product to doctors and hospitals or as B2C in form of a home-test kit through chemists or pharmacies and drugstores. Its comfortable application (using saliva from spitting and without intrusive nasal or buccal swabbing) will make it the preferred test.
4) Cost
The low production cost of the REPViT tests allows for the test to be used by all income levels and a number of tests can be used in sequence
5) Adaptability
The REPViT platform technology is easily adapted from the initial Covid-19/Influenza test and subsequently to other infectious diseases caused by viruses and bacteria.
This will allow governments, professionals and individuals to work together effectively to contain infectious diseases more efficiently and keep infection rates low.
The Team
The Team
The Team
Charles Lawrie
(DPhil, FRCPath)
Founder & Chief Scientific Officer (CSO)
_____________________________________
Charles is director of oncology research at Biodonostia Biomedical Research Centre (San Sebastián, Spain). He is also an Ikerbasque Research Professor, Marie Curie Fellow and University of Oxford Research Lecturer. A pioneer in diagnostic biomarkers in blood and other biological fluids.
The Team
The Team
Mónica Vicente (PhD)
Head of Scientific Development
_____________________________________
Mónica studied Pharmacy at UPV, followed by a PhD in the use of nanoparticles for diagnostics and therapy.
The Team
Marco Jimenez (PhD)
Chief Technical Officer (CTO)
_____________________________________
Marco is a physicist with a PhD in Photonics Engineering from University of Alcalá. He has spent time at CEA (Grenoble) and has significant experience in the biotech sector.
Javier Zubiria
Chief Operation Officer (COO)
_____________________________________
Javier graduated from the University of Deusto with a Psychology degree and later with a Masters in Entrepreneurship. Javier previously held a position in Tecnalia Ventures
Marta Luis
Operation Manager (OM)
_____________________________________
Marta obtained her first degree in Pharmacy before specializing in the Pharmaceutical Industry, including practical experience in pharmacovigilance.
Jonathan Leon
Medical Scientific Liaison Manager (MSL)
_____________________________________
Jonathan is the Medical Scientific Liaison Manager and holds a Chemistry degree as well as an official master degree in Applied Chemistry and Polymeric Materials. He has also been working in the surface engineering field and has participated in several R&D projects.